Clover Health's Jamie Reynoso Sells Shares

On June 15, 2026, Jamie Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (NasdaqGS: CLOV), sold 6,350 shares of the company. The transaction was valued at approximately $29,273, with an average sale price of $4.61 per share. This sale was part of a planned transaction under Rule 10b5-1.

Insider Buying and Selling at Clover Health Investments, Corp.

Reynoso's recent sale on June 15 was not his first. Just a few days prior, on June 11, he sold 7,289 shares at an average price of $4.91, also under a planned transaction. Other insiders have been active as well, including Chief Legal Officer Karen Soares, who sold 4,681 shares on June 15 at $4.61 per share, and Conrad Wai, CEO of Counterpart Health, who sold 220,426 shares on May 28 at $3.99 per share.

Other Institutional Activity in Clover Health

In recent institutional activity, BlackRock, Inc. reduced its holdings by 440,347 shares, ending with 31,840,512 shares valued at about $56.04 million. On the other hand, Vanguard Capital Management LLC significantly increased its position, adding 16,982,073 shares, bringing its total to 16,982,073 shares worth approximately $29.89 million. Geode Capital Management, LLC and State Street Corp also increased their stakes by 264,302 and 239,706 shares, respectively. Meanwhile, Charles Schwab Investment Management Inc grew its holdings by 609,571 shares.

Clover Health Investments Stock Snapshot

Shares of Clover Health Investments (NasdaqGS: CLOV) traded near $4.91. The company has a market cap of $2.53 billion and a forward P/E ratio of 48.1. Its stock has experienced a 52-week range from a low of $1.58 to a high of $5.18. Clover Health's 50-day moving average is $3.12, and its 200-day moving average is $2.67. The company has a current ratio of 1.33 and a quick ratio of 1.21, indicating its ability to cover short-term liabilities.

Recent Earnings

Clover Health reported revenue of $2.21 billion with a revenue growth rate of 62%. Despite the growth, the company posted a net margin of -2.58% and a return on equity of -16.86%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On June 11, 2026, UBS maintained a 'hold' rating on Clover Health with a price target of $4.75. Canaccord Genuity also maintained a 'buy' rating on June 4, 2026, with a target price of $4.20. Overall, the consensus recommendation is 'buy', with a mean target price of $4.15 based on three analyst opinions.

About Clover Health Investments, Corp.

Clover Health Investments, Corp., based in Wilmington, Delaware, offers Medicare Advantage plans across the United States. The company provides both preferred provider organization and health maintenance organization plans for Medicare-eligible individuals. It also operates the Clover Assistant, a technology platform designed to help physicians manage chronic diseases. Founded in 2014, Clover Health is led by CEO Andrew Toy and employs 724 people.

Bottom Line

Jamie Reynoso's planned sale of shares is part of routine insider activity at Clover Health. Investors often track these transactions for insights, but it's important to note that these sales are pre-scheduled. Clover Health's stock remains active with institutional investors, and analysts maintain a generally positive outlook with a 'buy' consensus. As always, 13F filings and insider sales are historical and may not reflect current holdings or intentions.